469 results on '"Cachay, Edward R."'
Search Results
2. Hepatitis C Virus Micro-elimination Among People With HIV in San Diego: Are We on Track?
- Author
-
Cheema, Jaskaran S, Mathews, William C, Wynn, Adriane, Bamford, Laura B, Torriani, Francesca J, Hill, Lucas A, Rajagopal, Amutha V, Yin, Jeffrey, Jain, Sonia, Garfein, Richard S, Cachay, Edward R, and Martin, Natasha K
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Digestive Diseases ,Clinical Research ,Behavioral and Social Science ,HIV/AIDS ,Infectious Diseases ,Chronic Liver Disease and Cirrhosis ,Liver Disease ,Hepatitis - C ,Emerging Infectious Diseases ,Hepatitis ,Infection ,Good Health and Well Being ,HCV ,HIV ,PWH ,modeling ,Clinical sciences ,Medical microbiology - Abstract
BackgroundRising incidence of hepatitis C virus (HCV) among people with HIV (PWH) in San Diego County (SDC) was reported. In 2018, the University of California San Diego (UCSD) launched a micro-elimination initiative among PWH, and in 2020 SDC launched an initiative to reduce HCV incidence by 80% across 2015-2030. We model the impact of observed treatment scale-up on HCV micro-elimination among PWH in SDC.MethodsA model of HCV transmission among people who inject drugs (PWID) and men who have sex with men (MSM) was calibrated to SDC. The model was additionally stratified by age, gender, and HIV status. The model was calibrated to HCV viremia prevalence among PWH in 2010, 2018, and 2021 (42.1%, 18.5%, and 8.5%, respectively), and HCV seroprevalence among PWID aged 18-39 years, MSM, and MSM with HIV in 2015. We simulate treatment among PWH, weighted by UCSD Owen Clinic (reaching 26% of HCV-infected PWH) and non-UCSD treatment, calibrated to achieve the observed HCV viremia prevalence. We simulated HCV incidence with observed and further treatment scale-up (+/- risk reductions) among PWH.ResultsObserved treatment scale-up from 2018 to 2021 will reduce HCV incidence among PWH in SDC from a mean of 429 infections/year in 2015 to 159 infections/year in 2030. County-wide scale-up to the maximum treatment rate achieved at UCSD Owen Clinic (in 2021) will reduce incidence by 69%, missing the 80% incidence reduction target by 2030 unless accompanied by behavioral risk reductions.ConclusionsAs SDC progresses toward HCV micro-elimination among PWH, a comprehensive treatment and risk reduction approach is necessary to reach 2030 targets.
- Published
- 2023
3. Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016
- Author
-
Kim, Jessica, Newcomb, Craig W, Carbonari, Dena M, Torgersen, Jessie, Althoff, Keri N, Kitahata, Mari M, Klein, Marina B, Moore, Richard D, Reddy, K Rajender, Silverberg, Michael J, Mayor, Angel M, Horberg, Michael A, Cachay, Edward R, Lim, Joseph K, Gill, M John, Chew, Kara, Sterling, Timothy R, Hull, Mark, Seaberg, Eric C, Kirk, Gregory D, Coburn, Sally B, Lang, Raynell, McGinnis, Kathleen A, Gebo, Kelly A, Napravnik, Sonia, Kim, H Nina, Re, Vincent Lo, and Research and Design of IeDEA, for the North American AIDS Cohort Collaboration on
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Hepatitis ,Infectious Diseases ,Digestive Diseases ,Hepatitis - B ,HIV/AIDS ,Sexually Transmitted Infections ,Liver Disease ,Infection ,Good Health and Well Being ,Female ,Humans ,Middle Aged ,Male ,Hepatitis B virus ,HIV Infections ,Acquired Immunodeficiency Syndrome ,Coinfection ,Cross-Sectional Studies ,DNA ,Viral ,Canada ,Hepatitis B ,Tenofovir ,North American AIDS Cohort Collaboration on Research and Design of IeDEA ,General Science & Technology - Abstract
A care cascade is a critical tool for evaluating delivery of care for chronic infections across sequential stages, starting with diagnosis and ending with viral suppression. However, there have been few data describing the hepatitis B virus (HBV) care cascade among people living with HIV infection who have HBV coinfection. We conducted a cross-sectional study among people living with HIV and HBV coinfection receiving care between January 1, 2012 and December 31, 2016 within 13 United States and Canadian clinical cohorts contributing data to the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). We evaluated each of the steps in this cascade, including: 1) laboratory-confirmed HBV infection, 2) tenofovir-based or entecavir-based HBV therapy prescribed, 3) HBV DNA measured during treatment, and 4) viral suppression achieved via undetectable HBV DNA. Among 3,953 persons with laboratory-confirmed HBV (median age, 50 years; 6.5% female; 43.8% were Black; 7.1% were Hispanic), 3,592 (90.9%; 95% confidence interval, 90.0-91.8%) were prescribed tenofovir-based antiretroviral therapy or entecavir along with their antiretroviral therapy regimen, 2,281 (57.7%; 95% confidence interval, 56.2-59.2%) had HBV DNA measured while on therapy, and 1,624 (41.1%; 95% confidence interval, 39.5-42.6) achieved an undetectable HBV DNA during HBV treatment. Our study identified significant gaps in measurement of HBV DNA and suppression of HBV viremia among people living with HIV and HBV coinfection in the United States and Canada. Periodic evaluation of the HBV care cascade among persons with HIV/HBV will be critical to monitoring success in completion of each step.
- Published
- 2023
4. People with HIV have a higher risk of COVID‐19 diagnosis but similar outcomes to the general population
- Author
-
Tang, Michael E, Gaufin, Thaidra, Anson, Ryan, Zhu, Wenhong, Mathews, William C, and Cachay, Edward R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,HIV/AIDS ,Infectious Diseases ,Clinical Research ,Prevention ,Infection ,Good Health and Well Being ,COVID-19 ,COVID-19 Testing ,HIV Infections ,Hospital Mortality ,Humans ,Retrospective Studies ,SARS-CoV-2 ,HIV ,outcomes ,Virology ,Clinical sciences ,Epidemiology - Abstract
BackgroundWe investigated the effect of HIV on COVID-19 outcomes with attention to selection bias due to differential testing and comorbidity burden.MethodsThis was a retrospective cohort analysis using four hierarchical outcomes: positive SARS-CoV-2 test, COVID-19 hospitalization, intensive care unit (ICU) admission and hospital mortality. The effect of HIV status was assessed using traditional covariate-adjusted, inverse probability-weighted (IPW) analysis based on covariate distributions for testing bias (testing IPWs), HIV infection status (HIV-IPWs) and combined models. Among people living with HIV (PWH), we evaluated whether CD4 count and HIV plasma viral load (pVL) discriminated between those who did and those who did not develop study outcomes using receiver operating characteristic analysis.ResultsBetween March and November 2020, 63 319 people were receiving primary care services at the University of California San Diego (UCSD), of whom 4017 were PWH. The PWH had 2.1 times the odds of a positive SARS-CoV-2 test compared with those without HIV after weighting for potential testing bias, comorbidity burden and HIV-IPW [95% confidence interval (CI): 1.6-2.8]. Relative to people without HIV, PWH did not have an increased rate of COVID-19 hospitalization after controlling for comorbidities and testing bias [adjusted incidence rate ratio (aIRR) = 0.5, 95% CI: 0.1-1.4]. PWH did not have a different rate of ICU admission (aIRR = 1.08, 95% CI: 0.31-3.80) or of in-hospital death (aIRR = 0.92, 95% CI: 0.08-10.94) in any examined model. Neither CD4 count nor pVL predicted any of the hierarchical outcomes among PWH.ConclusionsPeople living with HIV have a higher risk of COVID-19 diagnosis than those without HIV but the outcomes are similar in both groups.
- Published
- 2022
5. Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort
- Author
-
Ma, Jimmy, Nance, Robin M, Delaney, Joseph AC, Whitney, Bridget M, Bamford, Laura, Gravett, Ronnie M, Moore, Richard D, Napravnik, Sonia, Mayer, Kenneth H, Jacobson, Jeffrey M, Christopoulos, Katerina, Burkholder, Greer A, Keruly, Jeanne, Eron, Joseph J, Martin, Jeffrey, Cachay, Edward R, Saag, Michael S, Crane, Heidi M, and Kitahata, Mari M
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Infectious Diseases ,Sexually Transmitted Infections ,HIV/AIDS ,Infection ,Good Health and Well Being ,Acquired Immunodeficiency Syndrome ,Alanine ,Anti-HIV Agents ,Anti-Retroviral Agents ,Emtricitabine ,HIV ,HIV Infections ,Heterocyclic Compounds ,3-Ring ,Humans ,Tenofovir ,United States ,ART utilization ,ART treatment trends ,ART guidelines ,integrase inhibitor ,tenofovir alafenamide ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
Among 14 049 people with human immunodeficiency virus in care in 2019-2020, 96% were treated with antiretroviral therapy (ART). Current antiretroviral treatment patterns highlight high uptake of guideline-recommended ART regimens including second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) and tenofovir alafenamide, especially in antiretroviral-naive individuals initiating ART.
- Published
- 2022
6. Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March–December 2020
- Author
-
Shapiro, Adrienne E, Ignacio, Rachel A Bender, Whitney, Bridget M, Delaney, Joseph A, Nance, Robin M, Bamford, Laura, Wooten, Darcy, Keruly, Jeanne C, Burkholder, Greer, Napravnik, Sonia, Mayer, Kenneth H, Webel, Allison R, Kim, H Nina, Van Rompaey, Stephen E, Christopoulos, Katerina, Jacobson, Jeffrey, Karris, Maile, Smith, Davey, Johnson, Mallory O, Willig, Amanda, Eron, Joseph J, Hunt, Peter, Moore, Richard D, Saag, Michael S, Mathews, W Christopher, Crane, Heidi M, Cachay, Edward R, Kitahata, Mari M, and Systems, for the CFAR Network of Integrated Clinical
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Lung ,Prevention ,Coronaviruses ,Sexually Transmitted Infections ,Infectious Diseases ,Emerging Infectious Diseases ,Clinical Research ,HIV/AIDS ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,CD4 Lymphocyte Count ,COVID-19 ,COVID-19 Vaccines ,HIV Infections ,Humans ,Renal Insufficiency ,Chronic ,United States ,HIV ,CD4 count ,structural determinants of health ,immunosuppression ,CFAR Network of Integrated Clinical Systems ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundUnderstanding the spectrum of COVID-19 in people with HIV (PWH) is critical to provide clinical guidance and risk reduction strategies.SettingCenters for AIDS Research Network of Integrated Clinic System, a US multisite clinical cohort of PWH in care.MethodsWe identified COVID-19 cases and severity (hospitalization, intensive care, and death) in a large, diverse HIV cohort during March 1, 2020-December 31, 2020. We determined predictors and relative risks of hospitalization among PWH with COVID-19, adjusted for disease risk scores.ResultsOf 16,056 PWH in care, 649 were diagnosed with COVID-19 between March and December 2020. Case fatality was 2%; 106 (16.3%) were hospitalized, and 12 died. PWH with current CD4 count
- Published
- 2022
7. Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States
- Author
-
Ignacio, Rachel A Bender, Shapiro, Adrienne E, Nance, Robin M, Whitney, Bridget M, Delaney, Joseph AC, Bamford, Laura, Wooten, Darcy, Karris, Maile Y, Mathews, William C, Kim, Hyang Nina, Keruly, Jeanne, Burkholder, Greer, Napravnik, Sonia, Mayer, Kenneth H, Jacobson, Jeffrey, Saag, Michael, Moore, Richard D, Eron, Joseph J, Willig, Amanda L, Christopoulos, Katerina A, Martin, Jeffrey, Hunt, Peter W, Crane, Heidi M, Kitahata, Mari M, and Cachay, Edward R
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Infectious Diseases ,Emerging Infectious Diseases ,Clinical Research ,Sexually Transmitted Infections ,Substance Misuse ,Prevention ,Coronaviruses Disparities and At-Risk Populations ,Health Disparities ,Coronaviruses ,Social Determinants of Health ,Minority Health ,HIV/AIDS ,Good Health and Well Being ,Adult ,COVID-19 ,COVID-19 Testing ,Ethnicity ,Female ,HIV Infections ,Humans ,Incidence ,Middle Aged ,United States ,coronavirus disease 2019 acquisition ,HIV ,immune exhaustion ,racial disparities ,Centers for AIDS Research Network of Integrated Clinical Systems ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectivesTo define the incidence of clinically detected coronavirus disease 2019 (COVID-19) in people with HIV (PWH) in the United States and evaluate how racial and ethnic disparities, comorbidities, and HIV-related factors contribute to risk of COVID-19.DesignObservational study within the CFAR Network of Integrated Clinical Systems cohort in seven cities during 2020.MethodsWe calculated cumulative incidence rates of COVID-19 diagnosis among PWH in routine care by key characteristics including race/ethnicity, current and lowest CD4+ cell count, and geographic area. We evaluated risk factors for COVID-19 among PWH using relative risk regression models adjusted with disease risk scores.ResultsAmong 16 056 PWH in care, of whom 44.5% were black, 12.5% were Hispanic, with a median age of 52 years (IQR 40-59), 18% had a current CD4+ cell count less than 350 cells/μl, including 7% less than 200; 95.5% were on antiretroviral therapy (ART), and 85.6% were virologically suppressed. Overall in 2020, 649 PWH were diagnosed with COVID-19 for a rate of 4.94 cases per 100 person-years. The cumulative incidence of COVID-19 was 2.4-fold and 1.7-fold higher in Hispanic and black PWH respectively, than non-Hispanic white PWH. In adjusted analyses, factors associated with COVID-19 included female sex, Hispanic or black identity, lowest historical CD4+ cell count less than 350 cells/μl (proxy for CD4+ nadir), current low CD4+ : CD8+ ratio, diabetes, and obesity.ConclusionOur results suggest that the presence of structural racial inequities above and beyond medical comorbidities increased the risk of COVID-19 among PWH. PWH with immune exhaustion as evidenced by lowest historical CD4+ cell count or current low CD4+ : CD8+ ratio had greater risk of COVID-19.
- Published
- 2022
8. Early Outpatient Treatment for Covid-19 with Convalescent Plasma
- Author
-
Sullivan, David J, Gebo, Kelly A, Shoham, Shmuel, Bloch, Evan M, Lau, Bryan, Shenoy, Aarthi G, Mosnaim, Giselle S, Gniadek, Thomas J, Fukuta, Yuriko, Patel, Bela, Heath, Sonya L, Levine, Adam C, Meisenberg, Barry R, Spivak, Emily S, Anjan, Shweta, Huaman, Moises A, Blair, Janis E, Currier, Judith S, Paxton, James H, Gerber, Jonathan M, Petrini, Joann R, Broderick, Patrick B, Rausch, William, Cordisco, Marie-Elena, Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie C, Cruser, Daniel, Oei, Kevin, Abinante, Matthew, Hammitt, Laura L, Sutcliffe, Catherine G, Forthal, Donald N, Zand, Martin S, Cachay, Edward R, Raval, Jay S, Kassaye, Seble G, Foster, E Colin, Roth, Michael, Marshall, Christi E, Yarava, Anusha, Lane, Karen, McBee, Nichol A, Gawad, Amy L, Karlen, Nicky, Singh, Atika, Ford, Daniel E, Jabs, Douglas A, Appel, Lawrence J, Shade, David M, Ehrhardt, Stephan, Baksh, Sheriza N, Laeyendecker, Oliver, Pekosz, Andrew, Klein, Sabra L, Casadevall, Arturo, Tobian, Aaron AR, and Hanley, Daniel F
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Clinical Trials and Supportive Activities ,Neurodegenerative ,Patient Safety ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Ambulatory Care ,COVID-19 ,Disease Progression ,Double-Blind Method ,Hospitalization ,Humans ,Immunization ,Passive ,Treatment Outcome ,United States ,COVID-19 Serotherapy ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundPolyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain.MethodsIn this multicenter, double-blind, randomized, controlled trial, we evaluated the efficacy and safety of Covid-19 convalescent plasma, as compared with control plasma, in symptomatic adults (≥18 years of age) who had tested positive for severe acute respiratory syndrome coronavirus 2, regardless of their risk factors for disease progression or vaccination status. Participants were enrolled within 8 days after symptom onset and received a transfusion within 1 day after randomization. The primary outcome was Covid-19-related hospitalization within 28 days after transfusion.ResultsParticipants were enrolled from June 3, 2020, through October 1, 2021. A total of 1225 participants underwent randomization, and 1181 received a transfusion. In the prespecified modified intention-to-treat analysis that included only participants who received a transfusion, the primary outcome occurred in 17 of 592 participants (2.9%) who received convalescent plasma and 37 of 589 participants (6.3%) who received control plasma (absolute risk reduction, 3.4 percentage points; 95% confidence interval, 1.0 to 5.8; P = 0.005), which corresponded to a relative risk reduction of 54%. Evidence of efficacy in vaccinated participants cannot be inferred from these data because 53 of the 54 participants with Covid-19 who were hospitalized were unvaccinated and 1 participant was partially vaccinated. A total of 16 grade 3 or 4 adverse events (7 in the convalescent-plasma group and 9 in the control-plasma group) occurred in participants who were not hospitalized.ConclusionsIn participants with Covid-19, most of whom were unvaccinated, the administration of convalescent plasma within 9 days after the onset of symptoms reduced the risk of disease progression leading to hospitalization. (Funded by the Department of Defense and others; CSSC-004 ClinicalTrials.gov number, NCT04373460.).
- Published
- 2022
9. Risk factors for atrial fibrillation in a multicenter United States clinical cohort of people with HIV infection
- Author
-
Nance, Robin M, Delaney, Joseph AC, Floyd, James S, Saag, Michael S, Moore, Richard D, Keruly, Jeanne C, Kitahata, Mari M, Whitney, Bridget M, Mathews, W Chris, Cachay, Edward R, Burkholder, Greer, Willig, Amanda L, Eron, Joseph J, Napravnik, Sonia, Crane, Heidi M, and Heckbert, Susan R
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Cardiovascular ,Clinical Research ,Prevention ,Heart Disease ,Clinical Trials and Supportive Activities ,Infectious Diseases ,Patient Safety ,HIV/AIDS ,Aetiology ,2.1 Biological and endogenous factors ,Infection ,Anti-Retroviral Agents ,Atrial Fibrillation ,Cohort Studies ,HIV Infections ,Humans ,Risk Factors ,United States ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
To assess atrial fibrillation risk factors in people with HIV, we identified incident atrial fibrillation in a large clinical cohort of people receiving care. Compared with 970 controls without atrial fibrillation, the 97 with adjudicated incident atrial fibrillation were older, less likely Hispanic, and had more coronary disease, heart failure, and chronic obstructive pulmonary disease. In multivariable analysis, nonuse of antiretroviral therapy and prescription of antiretroviral regimens with multiple core agents were associated with increased atrial fibrillation risk.
- Published
- 2022
10. How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
- Author
-
Bloch, Evan M, Tobian, Aaron AR, Shoham, Shmuel, Hanley, Daniel F, Gniadek, Thomas J, Cachay, Edward R, Meisenberg, Barry R, Kafka, Kimberly, Marshall, Christi, Heath, Sonya L, Shenoy, Aarthi, Paxton, James H, Levine, Adam, Forthal, Donald, Fukuta, Yuriko, Huaman, Moises A, Ziman, Alyssa, Adamski, Jill, Gerber, Jonathan, Cruser, Daniel, Kassaye, Seble G, Mosnaim, Giselle S, Patel, Bela, Metcalf, Ryan A, Anjan, Shweta, Reisler, Ronald B, Yarava, Anusha, Lane, Karen, McBee, Nichol, Gawad, Amy, Raval, Jay S, Zand, Martin, Abinante, Matthew, Broderick, Patrick B, Casadevall, Arturo, Sullivan, David, and Gebo, Kelly A
- Subjects
Emerging Infectious Diseases ,Prevention ,Infectious Diseases ,Good Health and Well Being ,COVID-19 ,Humans ,Immunization ,Passive ,Outpatients ,Pandemics ,SARS-CoV-2 ,United States ,COVID-19 Serotherapy ,ambulatory care ,antibodies ,blood transfusion ,COVID-19 serotherapy ,monoclonal ,plasma ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Immunology ,Cardiovascular System & Hematology - Abstract
Convalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID-19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID-19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID-19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody-based therapies.
- Published
- 2022
11. Using computer-assisted content analysis to advance anal dysplasia natural history research
- Author
-
Cachay, Edward R, Hasteh, Farnaz, and Mathews, William Christopher
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Anal Canal ,Anus Neoplasms ,Atypical Squamous Cells of the Cervix ,Carcinoma in Situ ,HIV Infections ,Humans ,Retrospective Studies ,anal cytology ,anal dysplasia ,content analysis ,HIV ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectiveOur study aim was to validate the use of computer-aided narrative content analysis in the extraction of standard diagnostic categories using an archived cytology database that included individually overread reference classification.DesignA retrospective analysis of narrative anal cytology results collected on HIV-infected patients at the University of California, San Diego between January and December 2001.MethodsWe used computer-assisted content analysis extraction methodology using Wordstat 8.0 (Provalis Research) that operated using a classification dictionary that we developed for the following diagnostic categories: NAMC, ASCUS, LSIL, HSIL. We compared its accuracy to a physician overread manually extracted method: that classified each report into the most severe diagnostic category referenced in the narrative report. Agreement between content analysis mapped diagnostic categories and the reference category was evaluated using kappa agreement.ResultsDuring 2001, 901 patients underwent 997 anal cytological examinations as routine screening. By reference diagnostic category: 54 (5.4%) were unsatisfactory, 460 (46.1%) were NAMC, 291 (29.2%) were ASCUS, 131 (13.1%) were LSIL, and 61 (6.1%) were HSIL. Computer-aided content analysis extracted a single diagnosis from each report in 963 (96.2%) cases and two diagnoses in 38 (3.8%) cases. The Kappa agreement was 0.96 (0.019 s.e.). There were 29 cases classified ASCUS by reference category but LSIL by adjudicated content analysis. A focused review indicated that the over reader assigned reference category was in error.ConclusionComputer-aided narrative content analysis of anal cytology results yielded accurate and time-efficient classification into meaningful diagnostic categories that can be used to evaluate screening programs and modeling natural history.
- Published
- 2022
12. People with HIV Have Higher Risk of COVID-19 Diagnosis but Similar Outcomes than the General Population
- Author
-
Tang, Michael E, Gaufin, Thaidra, Anson, Ryan, Zhu, Wenhong, Mathews, William C, and Cachay, Edward R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Prevention ,Clinical Research ,HIV/AIDS ,Infectious Diseases ,Infection ,Good Health and Well Being - Abstract
Abstract: Background: We investigated the effect of HIV on COVID-19 outcomes with attention to selection bias due to differential testing and to comorbidity burden. Methods: Retrospective cohort analysis using four hierarchical outcomes: positive SARS-CoV-2 test, COVID-19 hospitalization, intensive care unit (ICU) admission, and hospital mortality. The effect of HIV status was assessed using traditional covariate-adjusted, inverse probability weighted (IPW) analysis based on covariate distributions for testing bias (testing IPWs), HIV infection status (HIV IPWs), and combined models. Among PWH, we evaluated whether CD4 count and HIV plasma viral load (pVL) discriminated between those who did or did not develop study outcomes using receiver operating characteristic analysis. Results: Between March and November 2020, 63,319 people were receiving primary care services at UCSD, of whom 4,017 were people living with HIV (PWH). PWH had 2.1 times the odds of a positive SARS-CoV-2 test compared to those without HIV after weighting for potential testing bias, comorbidity burden, and HIV-IPW (95% CI 1.6-2.8). Relative to persons without HIV, PWH did not have an increased rate of COVID-19 hospitalization after controlling for comorbidities and testing bias [adjusted incidence rate ratio (aIRR): 0.5, 95% CI: 0.1 – 1.4]. PWH had neither a different rate of ICU admission (aIRR:1.08, 95% CI; 0.31 – 3.80) nor in-hospital death (aIRR:0.92, 95% CI; 0.08 – 10.94) in any examined model. Neither CD4 count nor pVL predicted any of the hierarchical outcomes among PWH. Conclusions: PWH have a higher risk of COVID-19 diagnosis but similar outcomes compared to those without HIV. Summary point: After considering the effects of potential bias due to differential testing, comorbidities, and other patient characteristics, people with HIV had an increased rate of SARS-CoV-2 positivity and similar rates of hospitalization, ICU admission, and death.
- Published
- 2022
13. 46. Racial and Ethnic Disparities in COVID-19 Incidence among Persons with HIV in a Multisite-Cohort
- Author
-
Cachay, Edward R, Bamford, laura, Shapiro, Adrienne, Whitney, Bridget M, Wooten, Darcy, Karris, Maile, Smith, David, Bender Ignacio, Rachel A, Delaney, Joseph, robin, Nance, Keruly, Jeanne, Burkholder, Greer A, Napravnik, Sonia, Mayer, Kenneth, jacobson, Jeffrey M, Crane, Heidi, Kitahata, Mari, and Mathews, William C
- Subjects
Clinical Research ,Prevention ,HIV/AIDS ,Infectious Diseases ,Infection ,Good Health and Well Being - Abstract
Abstract: Background: Little is known about how race and ethnicity, imperfect (albeit accessible) proxies for structural racism, impact COVID-19 incidence among people with HIV (PWH). We report the cumulative incidence and incidence rate ratios (IRR) for COVID-19 in a long-term multi-site cohort of PWH across the US Figure 1. Cumulative incidence of COVID-19 in the CNICS cohort Methods: We examined COVID-19 cumulative incidence and IRR among PWH in care between 3/1/2020 and 12/31/2020 at seven sites in the CFAR Network of Integrated Clinical Systems (CNICS) cohort. We define COVID-19 incident case as having a laboratory-confirmed (RT-PCR/Ag) SARS-CoV-2 positive result or diagnosis verified by chart review. Reinfections were excluded. Results are presented as monthly and quarterly cumulative incidence and IRR with 95% CI stratified by CD4 count, self-reported race/ethnicity, and site. Follow-up was censored on the earliest of diagnosis of COVID-19 disease, loss to follow up, or 12/31/2020 Results: Among 15,780 PWH in care in the CNICS cohort during the study period, 62% were non-white, with a median (IQR) age of 52 (IQR 40-59), 95% were on antiretroviral therapy, 17% had a CD4 count less than 350, and 6% less than 200. Overall, 651 PWH tested positive for COVID-19 for a cumulative incidence of 4.13%. COVID-19 cumulative incidence increased from 0.77% at the end of the first quarter to 4.12% by the end of December 2020. At the peak of the pandemic in December 2020, the cumulative incidence in Black PWH was 1.68 fold higher than in white PWH (p=.033) and 2.35 fold higher in Hispanics than in whites (P< .0001), figure 1. Similarly, the IRR for COVID-19 was 1.71 (95% CI 1.42-2.07) for Black and 2.40 (95% CI 1.91-3.01) for Hispanic PWH relative to white. Although there was variation across sites, reflecting geographic differences in pandemic waves and access to COVID-19 testing, overall individual trends remained the same. COVID-19 cumulative incidence was similar across CD4 cell count strata Conclusion: Our results suggest effects of structural racial disparities on COVID-19 incidence in this diverse population of PWH across the US, with higher and disproportionate rates of COVID-19 in Black and Hispanic PWH. Incidence estimates are conservative because testing was not uniform, and no systematic testing was conducted Disclosures: Edward R. Cachay, MD, MAS, Gilead Science (Grant/Research Support, Advisor or Review Panel member)Merck Sharp & Dohme Corp (Grant/Research Support) Adrienne Shapiro, MD, PhD, Vir Biotechnology (Scientific Research Study Investigator) Darcy Wooten, MD, MS, Nothing to disclose Rachel A. Bender Ignacio, MD MPH, Abbvie (Individual(s) Involved: Self): Consultant; SeaGen (Individual(s) Involved: Self): Consultant Greer A. Burkholder, MD, MSPH, Eli Lilly (Grant/Research Support) Heidi Crane, MD, MPH, ViiV (Grant/Research Support)
- Published
- 2021
14. High prevalence of anal high-grade squamous intraepithelial lesions, and prevention through human papillomavirus vaccination, in young men who have sex with men living with HIV
- Author
-
Palefsky, Joel M, Lensing, Shelly Y, Belzer, Marvin, Lee, Jeannette, Gaur, Aditya H, Mayer, Kenneth, Futterman, Donna, Stier, Elizabeth A, Paul, Mary E, Chiao, Elizabeth Y, Reirden, Daniel, Goldstone, Stephen E, Tirado, Maribel, Cachay, Edward R, Barroso, Luis F, Da Costa, Maria, Darragh, Teresa M, Rudy, Bret J, Wilson, Craig M, Kahn, Jessica A, and Interventions, for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV AIDS
- Subjects
Pediatric Research Initiative ,Infectious Diseases ,HIV/AIDS ,Clinical Research ,Cervical Cancer ,Sexually Transmitted Infections ,HPV and/or Cervical Cancer Vaccines ,Immunization ,Vaccine Related ,Cancer ,Prevention ,Prevention of disease and conditions ,and promotion of well-being ,3.4 Vaccines ,Infection ,Good Health and Well Being ,Adolescent ,Adult ,Alphapapillomavirus ,Anal Canal ,Anus Neoplasms ,HIV ,HIV Infections ,Homosexuality ,Male ,Humans ,Male ,Papillomaviridae ,Papillomavirus Infections ,Papillomavirus Vaccines ,Prevalence ,Sexual Behavior ,Sexual and Gender Minorities ,Squamous Intraepithelial Lesions ,Vaccination ,Young Adult ,anal human papillomavirus infection ,quadrivalent HPV vaccine ,anal squamous intraepithelial lesions ,men who have sex with men ,human immunodeficiency virus ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
BackgroundMen who have sex with men (MSM) are at high risk for human papillomavirus (HPV)-related anal cancer. Little is known about the prevalence of low-grade squamous intraepithelial lesions (LSILs) and the anal cancer precursor, high-grade squamous intraepithelial lesions (HSILs), among young MSM with HIV (MSMLWH). HPV vaccination is recommended in this group, but its safety, immunogenicity, and protection against vaccine-type HPV infection and associated LSILs/HSILs have not been studied.MethodsTwo hundred and sixty MSMLWH aged 18-26 years were screened at 17 US sites for a clinical trial of the quadrivalent (HPV6,11,16,18) HPV (qHPV) vaccine. Those without HSILs were vaccinated at 0, 2, and 6 months. Cytology, high-resolution anoscopy with biopsies of lesions, serology, and HPV testing of the mouth/penis/scrotum/anus/perianus were performed at screening/month 0 and months 7, 12, and 24.ResultsAmong 260 MSMLWH screened, the most common reason for exclusion was detection of HSILs in 88/260 (34%). 144 MSMLWH were enrolled. 47% of enrollees were previously exposed to HPV16. No incident qHPV type-associated anal LSILs/HSILs were detected among men naive to that type, compared with 11.1, 2.2, 4.5, and 2.8 cases/100 person-years for HPV6,11,16,18-associated LSILs/HSILs, respectively, among those previously exposed to that type. qHPV was immunogenic and safe with no vaccine-associated serious adverse events.Conclusions18-26-year-old MSMLWH naive to qHPV vaccine types were protected against incident qHPV type-associated LSILs/HSILs. Given their high prevalence of HSILs, there is an urgent need to vaccinate young MSMLWH before exposure to vaccine HPV types, before initiating sexual activity, and to perform catch-up vaccination.
- Published
- 2021
15. The Human Immunodeficiency Virus (HIV) Index: Using a Patient-Reported Outcome on Engagement in HIV Care to Explain Suboptimal Retention in Care and Virologic Control
- Author
-
Christopoulos, Katerina A, Neilands, Torsten B, Koester, Kimberly A, Sauceda, John A, Dilworth, Samantha E, Mugavero, Michael J, Crane, Heidi M, Fredericksen, Rob J, Cachay, Edward R, Mayer, Kenneth H, Moore, Richard D, Napravnik, Sonia, and Johnson, Mallory O
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Prevention ,Infectious Diseases ,HIV/AIDS ,Sexually Transmitted Infections ,Mental Health ,Infection ,Good Health and Well Being ,Anti-HIV Agents ,Cohort Studies ,HIV ,HIV Infections ,Humans ,Patient Reported Outcome Measures ,Retention in Care ,United States ,Viral Load ,engagement in care ,retention in care ,viral suppression ,patient-reported outcome ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
BackgroundWe investigated the prospective association between a brief self-report measure of engagement in human immunodeficiency virus (HIV) care (the Index of Engagement in HIV Care; hereafter "Index") and suboptimal retention and viral suppression outcomes.MethodsThe Centers for AIDS Research Network of Integrated Clinical Systems cohort study combines medical record data with patient-reported outcomes from 8 HIV clinics in the United States, which from April 2016 to March 2017 included the 10-item Index. Multivariable logistic regression was used to estimate the risk and odds ratios of mean Index scores on 2 outcomes in the subsequent year: (1) not keeping ≥75% of scheduled HIV care appointments; and (2) for those with viral suppression at Index assessment, having viral load >200 copies/mL on ≥1 measurement. We also used generalized linear mixed models (GLMMs) to estimate the risk and odds ratios of appointment nonattendance or unsuppressed viral load at any given observation. We generated receiver operating characteristic curves for the full models overlaid with the Index as a sole predictor.ResultsThe mean Index score was 4.5 (standard deviation, 0.6). Higher Index scores were associated with lower relative risk of suboptimal retention (n = 2576; logistic regression adjusted risk ratio [aRR], 0.88 [95% confidence interval, .87-.88]; GLMM aRR, 0.85 [.83-.87]) and lack of sustained viral suppression (n = 2499; logistic regression aRR, 0.75 [.68-.83]; GLMM aRR, 0.74 [.68-.80]). The areas under the receiver operating characteristic curve for the full models were 0.69 (95% confidence interval, .67-.71) for suboptimal retention and 0.76 (.72-.79) for lack of sustained viral suppression.ConclusionsIndex scores are significantly associated with suboptimal retention and viral suppression outcomes.
- Published
- 2021
16. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard
- Author
-
Ajmera, Veeral H, Cachay, Edward R, Ramers, Christian B, Bassirian, Shirin, Singh, Seema, Bettencourt, Richele, Richards, Lisa, Hamilton, Gavin, Middleton, Michael, Fowler, Katie, Sirlin, Claude, and Loomba, Rohit
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Liver Disease ,Chronic Liver Disease and Cirrhosis ,Prevention ,HIV/AIDS ,Biomedical Imaging ,Infectious Diseases ,Hepatitis ,Digestive Diseases ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Inflammatory and immune system ,Infection ,Good Health and Well Being ,Biopsy ,Elasticity Imaging Techniques ,Female ,HIV Infections ,Humans ,Liver ,Magnetic Resonance Imaging ,Male ,Non-alcoholic Fatty Liver Disease ,Prospective Studies ,ROC Curve ,Reference Standards ,NASH ,steatosis ,MRI-PDFF ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
BackgroundControlled attenuation parameter (CAP) is an ultrasound-based point-of-care method to quantify liver fat; however, the optimal threshold for CAP to detect pathologic liver fat among persons living with human immunodeficiency virus (HIV; PLWH) is unknown. Therefore, we aimed to identify the diagnostic accuracy and optimal threshold of CAP for the detection of liver-fat among PLWH with magnetic resonance imaging proton-density fat fraction (MRI-PDFF) as the reference standard.MethodsPatients from a prospective single-center cohort of PLWH at risk for HIV-associated nonalcoholic fatty liver disease (NAFLD) who underwent contemporaneous MRI-PDFF and CAP assessment were included. Subjects with other forms of liver disease including viral hepatitis and excessive alcohol intake were excluded. Receiver operatic characteristic (ROC) curve analysis were performed to identify the optimal threshold for the detection of HIV-associated NAFLD (liver fat ≥ 5%).ResultsSeventy PLWH (90% men) at risk for NAFLD were included. The mean (± standard deviation) age and body mass index were 48.6 (±10.2) years and 30 (± 5.3) kg/m2, respectively. The prevalence of HIV-associated NAFLD (MRI-PDFF ≥ 5%) was 80%. The M and XL probes were used for 56% and 44% of patients, respectively. The area under the ROC curve of CAP for the detection of MRI-PDFF ≥ 5% was 0.82 (0.69-0.95) at the cut-point of 285 dB/m. The positive predictive value of CAP ≥ 285 dB/m was 93.2% in this cohort with sensitivity of 73% and specificity of 78.6%.ConclusionsThe optimal cut-point of CAP to correctly identify HIV-associated NAFLD was 285 dB/m, is similar to previously published cut-point for primary NAFLD and may be incorporated into routine care to identify patients at risk of HIV-associated NAFLD.
- Published
- 2021
17. Hepatitis C Knowledge and Recent Diagnosis Affect Hepatitis C Treatment Willingness in Persons Living With HIV
- Author
-
Cachay, Edward R, Torriani, Francesca J, Hill, Lucas, Rajagopal, Amutha, Yin, Jeffrey, Bamford, Laura, and Mathews, William C
- Subjects
Public Health ,Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Hepatitis ,HIV/AIDS ,Infectious Diseases ,Prevention ,Chronic Liver Disease and Cirrhosis ,Liver Disease ,Emerging Infectious Diseases ,Hepatitis - C ,Digestive Diseases ,Behavioral and Social Science ,7.1 Individual care needs ,Management of diseases and conditions ,Infection ,Good Health and Well Being ,Adult ,Coinfection ,Cross-Sectional Studies ,Female ,HIV Infections ,Hepacivirus ,Hepatitis C ,Hispanic or Latino ,Humans ,Male ,Middle Aged ,Prevalence ,Prospective Studies ,Sexual and Gender Minorities ,health literacy ,HCV knowledge ,HIV literacy ,treatment willingness ,and HIV ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundWe assessed the impact of health literacy and hepatitis C (HCV) knowledge on HCV treatment willingness among people living with HIV (PLWH) at an academic HIV clinic.MethodsCross-sectional analysis of PLWH coinfected with HCV who completed health literacy, HIV literacy, and HCV knowledge inventories. We estimated the prevalence of low health literacy, HIV knowledge, and HCV knowledge sampled from 3-comparison groups: PLWH not referred for HCV, referred but who "not showed" to the HCV clinic, and referred and attended the HCV clinic. We used mixed-model linear and logistic regression to ascertain predictors of low health literacy, HIV knowledge, HCV knowledge, and predictors of willingness to start HCV treatment.ResultsWe enrolled 151 PLWH; 17% were female, 38% non-White, and 60% without a high-school education. Approximately, 68% were men who have sex with men, of whom 62% used intravenous drugs. The prevalence of low health, HIV knowledge, and HCV knowledge was 10%, 32%, and 29%, respectively. Predictors of low health literacy were being Hispanic, cirrhotic, and not completing high-school education. Low HCV knowledge was observed in female, non-White, and those diagnosed with HCV for a decade. In adjusted analyses, PLWH living with HCV for a decade (OR: 0.23) were less likely to be very willing to be treated for HCV. By contrast, those with high HCV knowledge were more likely to be very willing to receive treatment (OR: 1.27).ConclusionLow HCV knowledge and living with HCV for at least a decade are under-recognized negative predictors for PLWH's willingness to receive HCV treatment.Clinical trials registrationClinicaTrials.gov identifier: NCT20170991.
- Published
- 2021
18. Screening for Sexually Transmitted Infections During Hepatitis C Treatment to Predict Reinfection Among People With HIV
- Author
-
Hill, Lucas A, Martin, Natasha K, Torriani, Francesca J, Jain, Sonia, Qin, Huifang, Mathews, Christopher, and Cachay, Edward R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Digestive Diseases ,Clinical Research ,Substance Misuse ,Hepatitis - C ,Behavioral and Social Science ,Hepatitis ,Liver Disease ,Sexually Transmitted Infections ,Infectious Diseases ,HIV/AIDS ,Prevention ,Chronic Liver Disease and Cirrhosis ,Emerging Infectious Diseases ,Drug Abuse (NIDA only) ,Infection ,Good Health and Well Being ,direct-acting antivirals ,hepatitis C ,HIV ,reinfection ,Clinical sciences ,Medical microbiology - Abstract
BackgroundLittle is known about the risk of hepatitis C virus (HCV) reinfection among people with HIV (PWH) in the direct-acting antiviral (DAA) era. We evaluate HCV reinfection rates in the DAA era and characterize presustained virologic response (SVR) behavioral risk factors associated with reinfection among PWH at the University of California, San Diego (UCSD).MethodsObservational longitudinal cohort of PWH treated with DAAs between 2014 and July 2019 who achieved SVR and had at least 1 subsequent HCV viral load measurement. HCV reinfection was defined as new HCV viremia after SVR. We examined whether screening for sexually transmitted infections (STIs) and substance use during the pre-SVR period could identify patients at greater risk for reinfection using exact Poisson regression to compare reinfection incidence rates between those with and without pre-SVR STIs and positive urine drug screens.ResultsEight out of 200 PWH were reinfected with HCV a median ~26 weeks after SVR over 328.1 person-years of follow-up (PYFU), for an incidence rate of 2.44/100 PYFU. The observed HCV reinfection rate was highest among men who have sex with men who inject drugs (MSM IDU; 4.63/100 PFYU) and those aged 30-39 years (6.80/100 PYFU). Having a positive gonorrhea/chlamydia test during the pre-SVR period was a predictor of HCV reinfection.ConclusionsThe HCV reinfection rate in the DAA era is similar to the rate observed in the interferon era in San Diego in PWH. STI screening during HCV treatment may help determine those at higher risk for HCV reinfection.
- Published
- 2021
19. Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach
- Author
-
Cachay, Edward R, Mena, Alvaro, Morano, Luis, Benitez, Laura, Maida, Ivana, Mendoza, Carmen DE, Hill, Lucas, Torriani, Francesca, Soriano, Vincente, and Mathews, WC
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Hepatitis - C ,Sexually Transmitted Infections ,Clinical Research ,Infectious Diseases ,Hepatitis ,Health Disparities ,Emerging Infectious Diseases ,HIV/AIDS ,Digestive Diseases ,Chronic Liver Disease and Cirrhosis ,Liver Disease ,Infection ,Good Health and Well Being ,Antiviral Agents ,Coinfection ,HIV Infections ,Hepacivirus ,Hepatitis C ,Hepatitis C ,Chronic ,Humans ,Liver Cirrhosis ,Prospective Studies ,Treatment Outcome ,HIV ,HCV ,liver decompensation ,DAA ,multidisciplinary ,HCV-HIV Transatlantic Research Network - Abstract
Fifty-four consecutive persons with HIV co-infected with hepatitis C virus (HCV) and liver decompensation were treated with direct-acting antivirals (DAA). The HCV treatment was delivered using a multidisciplinary HIV-coinfection model of care integrating sub-specialty services in 3 countries. Of those treated, 91% (95% confidence interval, 80.1 to 95.9) achieved sustained viral response, and only one person died during treatment. Our study provides evidence that HIV providers achieve excellent outcomes when treating patients with histories of decompensated liver disease, with characteristics similar to those studied using a multidisciplinary HIV-centered approach.
- Published
- 2021
20. Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study
- Author
-
Zhu, Xianming, Gebo, Kelly A, Abraham, Alison G, Habtehyimer, Feben, Patel, Eshan U, Laeyendecker, Oliver, Gniadek, Thomas J, Fernandez, Reinaldo E, Baker, Owen R, Ram, Malathi, Cachay, Edward R, Currier, Judith S, Fukuta, Yuriko, Gerber, Jonathan M, Heath, Sonya L, Meisenberg, Barry, Huaman, Moises A, Levine, Adam C, Shenoy, Aarthi, Anjan, Shweta, Blair, Janis E, Cruser, Daniel, Forthal, Donald N, Hammitt, Laura L, Kassaye, Seble, Mosnaim, Giselle S, Patel, Bela, Paxton, James H, Raval, Jay S, Sutcliffe, Catherine G, Abinante, Matthew, Broderick, Patrick, Cluzet, Valerie, Cordisco, Marie Elena, Greenblatt, Benjamin, Petrini, Joann, Rausch, William, Shade, David, Lane, Karen, Gawad, Amy L, Klein, Sabra L, Pekosz, Andrew, Shoham, Shmuel, Casadevall, Arturo, Bloch, Evan M, Hanley, Daniel, Sullivan, David J, and Tobian, Aaron A R
- Published
- 2023
- Full Text
- View/download PDF
21. Alcohol use and the longitudinal HIV care continuum for people with HIV who enrolled in care between 2011 and 2019
- Author
-
Lesko, Catherine R., Gnang, Jeanine S., Fojo, Anthony T., Hutton, Heidi E., McCaul, Mary E., Delaney, Joseph A., Cachay, Edward R., Mayer, Kenneth H., Crane, Heidi M., Batey, D. Scott, Napravnik, Sonia, Christopoulos, Katerina A., Lau, Bryan, and Chander, Geetanjali
- Published
- 2023
- Full Text
- View/download PDF
22. Multicenter Development and Validation of a Model for Predicting Retention in Care Among People with HIV
- Author
-
Ridgway, Jessica P., Ajith, Aswathy, Friedman, Eleanor E., Mugavero, Michael J., Kitahata, Mari M., Crane, Heidi M., Moore, Richard D., Webel, Allison, Cachay, Edward R., Christopoulos, Katerina A., Mayer, Kenneth H., Napravnik, Sonia, and Mayampurath, Anoop
- Published
- 2022
- Full Text
- View/download PDF
23. Effects of drug and hazardous alcohol use on having a detectable HIV viral load: An adherence mediation analysis
- Author
-
Cachay, Edward R., Moges, Tesfaye S., Qin, Huifang, Bamford, Laura, Grelotti, David J., and Mathews, Wm. Christopher
- Published
- 2023
- Full Text
- View/download PDF
24. The role of barriers to care on the propensity for hepatitis C virus nonreferral among people living with HIV.
- Author
-
Cachay, Edward R, Torriani, Francesca J, Hill, Lucas, Jain, Sonia, Del Real, Azucena, Qin, Huifang, Martin, Natasha, and Mathews, William C
- Subjects
Humans ,Hepacivirus ,Hepatitis C ,HIV Infections ,Substance-Related Disorders ,Antiviral Agents ,Housing ,Referral and Consultation ,Continuity of Patient Care ,Delivery of Health Care ,Integrated ,Health Services Accessibility ,California ,Coinfection ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology - Abstract
: Twenty-five percent of HIV/hepatitis C virus (HCV) coinfected patients were not referred for HCV treatment despite unrestricted access in California to direct-acting antivirals (DAA) in 2018. Having unstable housing and ongoing drug use directly affected HCV treatment nonreferral. However, psychiatric history and alcohol use impacted HCV treatment nonreferral through the mediation of not being engaged in HIV care. Achieving HCV elimination requires DAA treatment outside conventional health settings, including substance rehabilitation centers, mental health crisis houses, and homeless shelters.
- Published
- 2020
25. Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United States
- Author
-
Williams-Nguyen, Jessica, Hawes, Stephen E, Nance, Robin M, Lindström, Sara, Heckbert, Susan R, Kim, H Nina, Mathews, W Chris, Cachay, Edward R, Budoff, Matt, Hurt, Christopher B, Hunt, Peter W, Geng, Elvin, Moore, Richard D, Mugavero, Michael J, Peter, Inga, Kitahata, Mari M, Saag, Michael S, Crane, Heidi M, and Delaney, Joseph A
- Subjects
Epidemiology ,Health Sciences ,Heart Disease - Coronary Heart Disease ,Hepatitis ,Emerging Infectious Diseases ,Digestive Diseases ,Infectious Diseases ,Sexually Transmitted Infections ,Hepatitis - C ,Liver Disease ,Chronic Liver Disease and Cirrhosis ,Cardiovascular ,HIV/AIDS ,Heart Disease ,Infection ,Good Health and Well Being ,Adult ,Comorbidity ,Female ,HIV Infections ,Hepatitis C ,Chronic ,Humans ,Male ,Middle Aged ,Myocardial Infarction ,Risk Factors ,Socioeconomic Factors ,Substance Abuse ,Intravenous ,United States ,Viral Load ,chronic hepatitis C infection ,hepatitis C virus ,HIV ,HIV coinfection ,myocardial infarction ,people living with HIV ,type 2 myocardial infarction ,Mathematical Sciences ,Medical and Health Sciences - Abstract
Hepatitis C virus (HCV) infection is common among people living with human immunodeficiency virus (PLWH). Extrahepatic manifestations of HCV, including myocardial infarction (MI), are a topic of active research. MI is classified into types, predominantly atheroembolic type 1 MI (T1MI) and supply-demand mismatch type 2 MI (T2MI). We examined the association between HCV and MI among patients in the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems, a US multicenter clinical cohort of PLWH. MIs were centrally adjudicated and categorized by type using the Third Universal Definition of Myocardial Infarction. We estimated the association between chronic HCV (RNA+) and time to MI while adjusting for demographic characteristics, cardiovascular risk factors, clinical characteristics, and history of injecting drug use. Among 23,407 PLWH aged ≥18 years, there were 336 T1MIs and 330 T2MIs during a median of 4.7 years of follow-up between 1998 and 2016. HCV was associated with a 46% greater risk of T2MI (adjusted hazard ratio (aHR) = 1.46, 95% confidence interval (CI): 1.09, 1.97) but not T1MI (aHR = 0.87, 95% CI: 0.58, 1.29). In an exploratory cause-specific analysis of T2MI, HCV was associated with a 2-fold greater risk of T2MI attributed to sepsis (aHR = 2.01, 95% CI: 1.25, 3.24). Extrahepatic manifestations of HCV in this high-risk population are an important area for continued research.
- Published
- 2020
26. Association of Infection with Chronic Hepatitis C Virus and Myocardial Infarction in People Living with HIV in the United States
- Author
-
Williams-Nguyen, Jessica, Hawes, Stephen E, Nance, Robin M, Lindström, Sara, Heckbert, Susan R, Kim, H Nina, Mathews, W Chris, Cachay, Edward R, Budoff, Matt, Hurt, Christopher B, Hunt, Peter W, Geng, Elvin, Moore, Richard D, Mugavero, Michael J, Peter, Inga, Kitahata, Mari M, Saag, Michael S, Crane, Heidi M, and Delaney, Joseph A
- Subjects
HIV/AIDS ,Digestive Diseases ,Hepatitis ,Cardiovascular ,Heart Disease ,Emerging Infectious Diseases ,Heart Disease - Coronary Heart Disease ,Chronic Liver Disease and Cirrhosis ,Hematology ,Liver Disease ,Hepatitis - C ,Infectious Diseases ,Infection ,Good Health and Well Being ,Adult ,Comorbidity ,Female ,HIV Infections ,Hepatitis C ,Chronic ,Humans ,Male ,Middle Aged ,Myocardial Infarction ,Risk Factors ,Socioeconomic Factors ,Substance Abuse ,Intravenous ,United States ,Viral Load ,chronic hepatitis C infection ,hepatitis C virus ,HIV ,HIV coinfection ,myocardial infarction ,people living with HIV ,type 2 myocardial infarction ,Mathematical Sciences ,Medical and Health Sciences ,Epidemiology - Abstract
Hepatitis C virus (HCV) infection is common among people living with human immunodeficiency virus (PLWH). Extrahepatic manifestations of HCV, including myocardial infarction (MI), are a topic of active research. MI is classified into types, predominantly atheroembolic type 1 MI (T1MI) and supply-demand mismatch type 2 MI (T2MI). We examined the association between HCV and MI among patients in the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems, a US multicenter clinical cohort of PLWH. MIs were centrally adjudicated and categorized by type using the Third Universal Definition of Myocardial Infarction. We estimated the association between chronic HCV (RNA+) and time to MI while adjusting for demographic characteristics, cardiovascular risk factors, clinical characteristics, and history of injecting drug use. Among 23,407 PLWH aged ≥18 years, there were 336 T1MIs and 330 T2MIs during a median of 4.7 years of follow-up between 1998 and 2016. HCV was associated with a 46% greater risk of T2MI (adjusted hazard ratio (aHR) = 1.46, 95% confidence interval (CI): 1.09, 1.97) but not T1MI (aHR = 0.87, 95% CI: 0.58, 1.29). In an exploratory cause-specific analysis of T2MI, HCV was associated with a 2-fold greater risk of T2MI attributed to sepsis (aHR = 2.01, 95% CI: 1.25, 3.24). Extrahepatic manifestations of HCV in this high-risk population are an important area for continued research.
- Published
- 2020
27. PREVALENCE AND CORRELATES OF SARS-COV-2 VACCINE UPTAKE AND HESITANCY AMONG PEOPLE WITH HIV ACROSS THE U.S.
- Author
-
Spinelli, Matthew A., primary, Johnson, Mallory O., additional, Lisha, Nadra E., additional, Jain, Jennifer P., additional, Moreira, Carlos V., additional, Glidden, David V., additional, Burkholder, Greer A., additional, Crane, Heidi M., additional, Jacobson, Jeffrey M., additional, Cachay, Edward R., additional, Mayer, Kenneth H., additional, Napravnik, Sonia, additional, Moore, Richard D., additional, Gandhi, Monica, additional, and Christopoulos, Katerina A., additional
- Published
- 2024
- Full Text
- View/download PDF
28. Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States
- Author
-
Chen, Po-Hung, Yenokyan, Karine, Fojo, Anthony T., Hutton, Heidi E., Lesko, Catherine R., McCaul, Mary E., Yang, Cui, Cachay, Edward R., Crane, Heidi M., Jacobson, Jeffrey M., Kim, H. Nina, Kitahata, Mari M., Mayer, Kenneth H., Moore, Richard D., Napravnik, Sonia, Saag, Michael, Lau, Bryan, and Chander, Geetanjali
- Published
- 2022
- Full Text
- View/download PDF
29. Associations between drug and alcohol use, smoking, and frailty among people with HIV across the United States in the current era of antiretroviral treatment
- Author
-
Crane, Heidi M., Ruderman, Stephanie A, Whitney, Bridget M, Nance, Robin M, Drumright, Lydia N., Webel, Allison R., Willig, Amanda L., Saag, Michael S., Christopoulos, Katerina, Greene, Meredith, Hahn, Andrew W., Eron, Joseph J., Napravnik, Sonia, Mathews, William Christopher, Chander, Geetanjali, McCaul, Mary E., Cachay, Edward R., Mayer, Kenneth H., Landay, Alan, Austad, Steven, Ma, Jimmy, Kritchevsky, Stephen B., Pandya, Chintan, Achenbach, Chad, Cartujano-Barrera, Francisco, Kitahata, Mari, Delaney, Joseph AC, and Kamen, Charles
- Published
- 2022
- Full Text
- View/download PDF
30. Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.
- Author
-
Lo Re, Vincent, Newcomb, Craig W, Carbonari, Dena M, Roy, Jason A, Althoff, Keri N, Kitahata, Mari M, Reddy, K Rajender, Lim, Joseph K, Silverberg, Michael J, Mayor, Angel M, Horberg, Michael A, Cachay, Edward R, Kirk, Gregory D, Hull, Mark, Gill, John, Sterling, Timothy R, Kostman, Jay R, Peters, Marion G, Moore, Richard D, Klein, Marina B, and Kim, H Nina
- Subjects
Public Health ,Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Hepatitis ,Clinical Research ,Digestive Diseases ,HIV/AIDS ,Infectious Diseases ,Alcoholism ,Alcohol Use and Health ,Chronic Liver Disease and Cirrhosis ,Substance Misuse ,Hepatitis - B ,Rare Diseases ,Sexually Transmitted Infections ,Liver Disease ,Liver Cancer ,Cancer ,Aetiology ,2.1 Biological and endogenous factors ,Infection ,Good Health and Well Being ,Adult ,CD4 Lymphocyte Count ,Canada ,Carcinoma ,Hepatocellular ,End Stage Liver Disease ,Esophageal and Gastric Varices ,Female ,Gastrointestinal Hemorrhage ,HIV Infections ,Hepatitis B ,Humans ,Liver ,Liver Cirrhosis ,Liver Neoplasms ,Male ,Middle Aged ,Retrospective Studies ,Risk Factors ,United States ,hepatitis B ,HIV ,end-stage liver disease ,hepatocellular carcinoma ,coinfection ,North American AIDS Cohort Collaboration on Research and Design of IeDEA ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundHepatitis B virus (HBV) infection is a leading cause of end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) in HIV. Factors contributing to the high rates of liver complications among HIV/HBV-coinfected individuals remain unknown.SettingNorth American AIDS Cohort Collaboration on Research and Design.MethodsWe performed a retrospective cohort study among HIV/HBV-coinfected patients in 10 US and Canadian cohorts of the North American AIDS Cohort Collaboration on Research and Design that validated ESLD (ascites, spontaneous bacterial peritonitis, variceal hemorrhage, and/or hepatic encephalopathy) and HCC diagnoses from 1996 to 2010. Multivariable Cox regression was used to examine adjusted hazard ratios [aHRs with 95% confidence interval (CIs)] of liver complications (first occurrence of ESLD or HCC) associated with hypothesized determinants and with increasing durations of HIV suppression (≤500 copies/mL).ResultsAmong 3573 HIV/HBV patients with 13,790 person-years of follow-up, 111 liver complications occurred (incidence rate = 8.0 [95% CI: 6.6 to 9.7] events/1000 person-years). Rates of liver complication were increased with non-black/non-Hispanic race [aHR = 1.76 (1.13-2.74)], diabetes mellitus [aHR = 2.07 (1.20-3.57)], lower time-updated CD4 cell count [3.25: aHR = 9.79 (5.73-16.74); 1.45-3.25: aHR = 3.20 (1.87-5.47) versus FIB-4
- Published
- 2019
31. Marijuana Use Is Not Associated With Changes in Opioid Prescriptions or Pain Severity Among People Living With HIV and Chronic Pain.
- Author
-
Merlin, Jessica S, Long, Dustin, Becker, William C, Cachay, Edward R, Christopolous, Katerina A, Claborn, Kasey R, Crane, Heidi M, Edelman, Eva Jennifer, Lovejoy, Travis I, Mathews, William Christopher, Morasco, Benjamin J, Napravnik, Sonia, OʼCleirigh, Connall, Saag, Michael S, Starrels, Joanna L, Gross, Robert, and Liebschutz, Jane M
- Subjects
Substance Misuse ,Behavioral and Social Science ,Chronic Pain ,Infectious Diseases ,Pain Research ,HIV/AIDS ,Drug Abuse (NIDA only) ,7.1 Individual care needs ,Management of diseases and conditions ,Analgesics ,Opioid ,Female ,Follow-Up Studies ,HIV Infections ,Humans ,Logistic Models ,Male ,Marijuana Smoking ,Marijuana Use ,Medical Marijuana ,Middle Aged ,Multivariate Analysis ,Opioid-Related Disorders ,Prescription Drugs ,Prospective Studies ,Self Report ,Surveys and Questionnaires ,Treatment Outcome ,United States ,marijuana ,opioids ,pain ,HIV ,Clinical Sciences ,Public Health and Health Services ,Virology - Abstract
BackgroundPeople living with HIV (PLWH) commonly report marijuana use for chronic pain, although there is limited empirical evidence to support its use. There is hope that marijuana may reduce prescription opioid use. Our objective was to investigate whether marijuana use among PLWH who have chronic pain is associated with changes in pain severity and prescribed opioid use (prescribed opioid initiation and discontinuation).MethodsParticipants completed self-report measures of chronic pain and marijuana use at an index visit and were followed up for 1 year in the Center for AIDS Research Network of Integrated Clinical Systems (CNICS). Self-reported marijuana use was the exposure variable. Outcome variables were changes in pain and initiation or discontinuation of opioids during the study period. The relationship between exposure and outcomes was assessed using generalized linear models for pain and multivariable binary logistic regression models for opioid initiation/discontinuation.ResultsOf 433 PLWH and chronic pain, 28% reported marijuana use in the past 3 months. Median pain severity at the index visit was 6.3/10 (interquartile range 4.7-8.0). Neither increases nor decreases in marijuana use were associated with changes in pain severity, and marijuana use was not associated with either lower odds of opioid initiation or higher odds of opioid discontinuation.ConclusionsWe did not find evidence that marijuana use in PLWH is associated with improved pain outcomes or reduced opioid prescribing. This suggests that caution is warranted when counseling PLWH about potential benefits of recreational or medical marijuana.
- Published
- 2019
32. Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.
- Author
-
Kahn, Jessica A, Belzer, Marvin, Chi, Xiaofei, Lee, Jeannette, Gaur, Aditya H, Mayer, Kenneth, Martinez, Jaime, Futterman, Donna C, Stier, Elizabeth A, Paul, Mary E, Chiao, Elizabeth Y, Reirden, Daniel, Goldstone, Steven E, Ortiz Martinez, Ana P, Cachay, Edward R, Barroso, Luis F, Da Costa, Maria, Wilson, Craig M, Palefsky, Joel M, and AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions
- Subjects
AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions ,Mouth ,Genitalia ,Male ,Humans ,Papillomaviridae ,Papillomavirus Infections ,HIV Infections ,Prevalence ,Homosexuality ,Male ,Adolescent ,Adult ,Anal Canal ,Male ,Young Adult ,Adolescents ,Clinical trials ,HIV ,Human papillomavirus ,Men who have sex with men ,Vaccine ,Genitalia ,Homosexuality - Abstract
The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18-26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants' mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11-6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03-5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16-10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. CLINICAL TRIAL NUMBER: NCT01209325.
- Published
- 2019
33. Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015.
- Author
-
Chaillon, Antoine, Sun, Xiaoying, Cachay, Edward R, Looney, David, Wyles, David, Garfein, Richard S, Martin, Thomas CS, Jain, Sonia, Mehta, Sanjay R, Smith, Davey M, Little, Susan J, and Martin, Natasha K
- Subjects
HCV ,HIV ,incidence ,men who have sex with men ,Liver Disease ,Drug Abuse (NIDA Only) ,Chronic Liver Disease and Cirrhosis ,Emerging Infectious Diseases ,Digestive Diseases ,Substance Abuse ,Clinical Research ,HIV/AIDS ,Hepatitis - C ,Prevention ,Infectious Diseases ,Sexual and Gender Minorities (SGM/LGBT*) ,Hepatitis ,Behavioral and Social Science ,2.2 Factors relating to the physical environment ,Infection - Abstract
BackgroundLittle is known about the hepatitis C virus (HCV) epidemic among HIV-infected men who have sex with men (HIV+ MSM) in the United States. In this study, we aimed to determine the incidence of primary HCV infection among HIV+ MSM in San Diego, California.MethodsWe performed a retrospective cohort analysis of HCV infection among HIV+ MSM attending 2 of the largest HIV clinics in San Diego. Incident HCV infection was assessed among HIV+ MSM with a negative anti-HCV test and subsequent HCV test between 2000 and 2017, with data censored to 2015. HCV reinfection was assessed among HIV+ MSM successfully treated for HCV between 2008 and 2015. Infection/reinfection rates were calculated using person-time methods.ResultsAmong 3068 initially HCV-seronegative HIV+ MSM, 178 new infections occurred over 15 796 person-years, giving an incidence of 1.13 per 100 person-years (/100py; 95% confidence interval [CI], 0.97-1.31). Incidence was stable from 2000 to 2014 (0.83/100py; 95% CI, 0.41-1.48), with an increase to 3.01/100py (95% CI, 1.97-4.42) in 2015 (P = .02). Among 43 successfully treated patients, 3 were reinfected.ConclusionsHCV incidence is high among HIV+ MSM in San Diego, with evidence suggesting a recent increase in 2015. Strong HCV testing guidelines and active prevention efforts among HIV+ MSM are urgently needed that include rapid diagnosis, treatment, and risk reduction.
- Published
- 2019
34. Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study.
- Author
-
Kim, H Nina, Nance, Robin M, Williams-Nguyen, Jessica S, Chris Delaney, JA, Crane, Heidi M, Cachay, Edward R, Martin, Jeffrey, Mathews, W Christopher, Chander, Geetanjali, Franco, Ricardo, Hurt, Christopher B, Geng, Elvin H, Rodriguez, Benigno, Moore, Richard D, Saag, Michael S, Kitahata, Mari M, and Centers for AIDS Research Network of Integrated Clinical Systems
- Subjects
Centers for AIDS Research Network of Integrated Clinical Systems ,HIV ,direct-acting antiviral ,hepatitis C virus ,HIV/AIDS ,Liver Disease ,Infectious Diseases ,Hepatitis - C ,Chronic Liver Disease and Cirrhosis ,Drug Abuse (NIDA Only) ,Substance Abuse ,Clinical Research ,Clinical Trials and Supportive Activities ,Brain Disorders ,Hepatitis ,Mental Health ,Emerging Infectious Diseases ,Digestive Diseases ,6.1 Pharmaceuticals ,Infection ,Mental health - Abstract
BackgroundDirect-acting antiviral (DAA) therapy have been shown to be highly successful in clinical trials and observational studies, but less is known about treatment success in patients with a high burden of comorbid conditions, including mental health and substance use disorders. We evaluated DAA effectiveness across a broad spectrum of patients with human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection in routine clinical care, including those with psychosocial comorbid conditions.MethodsThe primary end point was sustained virologic response (SVR), defined as HCV RNA not detected or 3.25) was present in 24%, and 17% were interferon treatment experienced; 96% had genotype 1 infection and 432 (81%) had received ledipasvir-sofosbuvir. SVR occurred in 96.5% (95% CI, 94.5%-97.9%). Patients who were black, treatment experienced, or cirrhotic all had SVR rates >95%. Patients with depression and/or anxiety, psychotic disorder, illicit drug use, or alcohol use disorder also had high SVR rates, ranging from 95.4% to 96.8%. The only factor associated with lower SVR rate was early discontinuation (77.8%; 95% CI, 52.4%-93.6%). Similar results were seen in multiply imputed data sets.ConclusionsOur study represents a large multicenter examination of DAA therapy in HIV/HCV-coinfected patients. The broad treatment success we observed across this diverse group of patients with significant comorbid conditions is highly affirming and argues for widespread implementation of DAA therapy.
- Published
- 2019
35. Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus
- Author
-
Cachay, Edward R, Mena, Alvaro, Morano, Luis, Benitez, Laura, Maida, Ivana, Ballard, Craig, Hill, Lucas, Torriani, Francesca, Castro, Angeles, Dore, Elena, Castro, Sheila, de Mendoza Fernández, Carmen, Soriano, Vicente, Mathews, C, and Cohort, HCV-TREN
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Emerging Infectious Diseases ,Hepatitis ,Hepatitis - C ,Liver Disease ,Chronic Liver Disease and Cirrhosis ,Digestive Diseases ,HIV/AIDS ,Infectious Diseases ,Substance Misuse ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,DAA ,drug use ,HCV treatment failure ,HIV ,mental illness ,HCV-TREN Cohort ,Clinical sciences ,Medical microbiology - Abstract
BackgroundLittle is known about the influence of ongoing barriers to care in the persistence of hepatitis C virus (HCV) viremia after treatment with direct-acting antivirals (DAAs) among people living with human immunodeficiency virus (PLWH).MethodsWe conducted a retrospective cohort analysis of PLWH treated through the standard of care in 3 Western countries, to investigate the predictors of HCV treatment failure (clinical or virologic), defined as having a detectable serum HCV ribonucleic acid within 12 weeks after DAA discontinuation. In addition to HCV and liver-related predictors, we collected data on ongoing illicit drug use, alcohol abuse, mental illness, and unstable housing. Logistic regression analyses were used to identify predictors of HCV treatment failure.ResultsBetween January 2014 and December 2017, 784 PLWH were treated with DAA, 7% (n = 55) of whom failed HCV therapy: 50.9% (n = 28) had a clinical failure (discontinued DAA therapy prematurely, died, or were lost to follow-up), 47.3% (n = 26) had an HCV virologic failure, and 1 (1.8%) was reinfected with HCV. Ongoing drug use (odds ratio [OR] = 2.60) and mental illness (OR = 2.85) were independent predictors of any HCV treatment failure. Having both present explained 20% of the risk of any HCV treatment failure due to their interaction (OR = 7.47; P < .0001). Predictors of HCV virologic failure were ongoing illicit drug use (OR = 2.75) and advanced liver fibrosis (OR = 2.29).ConclusionsPeople living with human immunodeficiency virus with ongoing illicit drug use, mental illness, and advanced liver fibrosis might benefit from enhanced DAA treatment strategies to reduce the risk of HCV treatment failure.
- Published
- 2019
36. Evaluation of a computer-based and counseling support intervention to improve HIV patients’ viral loads
- Author
-
Marks, Gary, O’Daniels, Christine, Grossman, Cynthia, Crepaz, Nicole, Rose, Charles E, Patel, Unnati, Stirratt, Michael J, Gardner, Lytt I, Cachay, Edward R, Mathews, William C, Drainoni, Mari-Lynn, Sullivan, Meg, Bradley-Springer, Lucy, Corwin, Marla, Gordon, Christopher, Rodriguez, Allan, Dhanireddy, Shireesha, and Giordano, Thomas P
- Subjects
Health Services and Systems ,Health Sciences ,HIV/AIDS ,Infectious Diseases ,Substance Misuse ,Health Services ,Prevention ,Clinical Research ,Clinical Trials and Supportive Activities ,Behavioral and Social Science ,Infection ,Good Health and Well Being ,Adult ,Anti-HIV Agents ,Counseling ,Female ,HIV Infections ,Humans ,Male ,Medication Adherence ,Middle Aged ,Viral Load ,HIV ,AIDS ,viral load ,computer intervention ,counseling ,Public Health and Health Services ,Psychology ,Public Health ,Public health ,Sociology ,Clinical and health psychology - Abstract
We sought to integrate a brief computer and counseling support intervention into the routine practices of HIV clinics and evaluate effects on patients' viral loads. The project targeted HIV patients in care whose viral loads exceeded 1000 copies/ml at the time of recruitment. Three HIV clinics initiated the intervention immediately, and three other HIV clinics delayed onset for 16 months and served as concurrent controls for evaluating outcomes. The intervention components included a brief computer-based intervention (CBI) focused on antiretroviral therapy adherence; health coaching from project counselors for participants whose viral loads did not improve after doing the CBI; and behavioral screening and palm cards with empowering messages available to all patients at intervention clinics regardless of viral load level. The analytic cohort included 982 patients at intervention clinics and 946 patients at control clinics. Viral loads were assessed at 270 days before recruitment, at time of recruitment, and +270 days later. Results indicated that both the control and intervention groups had significant reductions in viral load, ending with approximately the same viral level at +270 days. There was no evidence that the CBI or the targeted health coaching was responsible for the viral reduction in the intervention group. Results may stem partially from statistical regression to the mean in both groups. Also, clinical providers at control and intervention clinics may have taken action (e.g., conversations with patients, referrals to case managers, adherence counselors, mental health, substance use specialists) to help their patients reduce their viral loads. In conclusion, neither a brief computer-based nor targeted health coaching intervention reduced patients' viral loads beyond levels achieved with standard of care services available to patients at well-resourced HIV clinics.
- Published
- 2018
37. Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease
- Author
-
Caussy, Cyrielle, Chen, Jun, Alquiraish, Mosab H, Cepin, Sandra, Nguyen, Phirum, Hernandez, Carolyn, Yin, Meng, Bettencourt, Ricki, Cachay, Edward R, Jayakumar, Saumya, Fortney, Lynda, Hooker, Jonathan, Sy, Ethan, Valasek, Mark A, Rizo, Emily, Richards, Lisa, Brenner, David, Sirlin, Claude B, Ehman, Richard L, and Loomba, Rohit
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Chronic Liver Disease and Cirrhosis ,Liver Disease ,Digestive Diseases ,Oral and gastrointestinal ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Biopsy ,Body Mass Index ,Cross-Sectional Studies ,Elasticity Imaging Techniques ,Female ,Humans ,Liver Cirrhosis ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Non-alcoholic Fatty Liver Disease ,Obesity ,Young Adult ,Liver Fibrosis ,Nonalcoholic Fatty Liver Disease ,Magnetic Resonance Elastography ,Transient Elastography ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Background & aimsMagnetic resonance elastography (MRE) and transient elastography (TE) are noninvasive techniques used to detect liver fibrosis in nonalcoholic fatty liver disease. MRE detects fibrosis more accurately than TE, but MRE is more expensive, and the concordance between MRE and TE have not been optimally assessed in obese patients. It is important to determine under which conditions TE and MRE produce the same readings, so that some patients can simply undergo TE evaluation to detect fibrosis. We aimed to assess the association between body mass index (BMI) and discordancy between MRE and TE findings, using liver biopsy as the reference, and validated our findings in a separate cohort.MethodsWe performed a cross-sectional study of 119 adults with nonalcoholic fatty liver disease who underwent MRE, TE with M and XL probe, and liver biopsy analysis from October 2011 through January 2017 (training cohort). MRE and TE results were considered to be concordant if they found patients to have the same stage fibrosis as liver biopsy analysis. We validated our findings in 75 adults with nonalcoholic fatty liver disease who underwent contemporaneous MRE, TE, and liver biopsy at a separate institution from March 2010 through May 2013. The primary outcome was rate of discordance between MRE and TE in determining stage of fibrosis (stage 2-4 vs 0-1). Secondary outcomes were the rate of discordance between MRE and TE in determining dichotomized stage of fibrosis (1-4 vs 0, 3-4 vs 0-2, and 4 vs 0-3).ResultsIn the training cohort, there was 43.7% discordance in findings from MRE versus TE. BMI associated significantly with discordance in findings from MRE versus TE (odds ratio, 1.69; 95% confidence interval, 1.15-2.51; P = .008) after multivariable adjustment by age and sex. The findings were confirmed in the validation cohort: there was 45.3% discordance in findings from MRE versus TE. BMI again associated significantly with discordance in findings from MRE versus TE (odds ratio, 1.52; 95% confidence interval, 1.04-2.21; P = .029) after multivariable adjustment by age and sex.ConclusionsWe identified and validated BMI as a factor significantly associated with discordance of findings from MRE versus TE in assessment of fibrosis stage. The degree of discordancy increases with BMI.
- Published
- 2018
38. Chronic obstructive pulmonary disease and the risk for myocardial infarction by type in people with HIV
- Author
-
Crothers, Kristina, Nance, Robin M., Whitney, Bridget M., Harding, Barbara N., Heckbert, Susan R., Budoff, Matthew J., Mathews, William C., Bamford, Laura, Cachay, Edward R., Eron, Joseph J., Napravnik, Sonia, Moore, Richard D., Keruly, Jeanne C., Willig, Amanda, Burkholder, Greer, Feinstein, Matthew J., Saag, Michael S., Kitahata, Mari M., Crane, Heidi M., and Delaney, Joseph A.C.
- Published
- 2023
- Full Text
- View/download PDF
39. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
- Author
-
Li, Maggie, Beck, Evan J., Laeyendecker, Oliver, Eby, Yolanda, Tobian, Aaron A.R., Caturegli, Patrizio, Wouters, Camille, Chiklis, Gregory R., Block, William, McKie, Robert O., Joyner, Michael J., Wiltshire, Timothy D., Dietz, Allan B., Gniadek, Thomas J., Shapiro, Arell J., Yarava, Anusha, Lane, Karen, Hanley, Daniel F., Bloch, Evan M., Shoham, Shmuel, Cachay, Edward R., Meisenberg, Barry R., Huaman, Moises A., Fukuta, Yuriko, Patel, Bela, Heath, Sonya L., Levine, Adam C., Paxton, James H., Anjan, Shweta, Gerber, Jonathan M., Gebo, Kelly A., Casadevall, Arturo, Pekosz, Andrew, and Sullivan, David J.
- Published
- 2022
- Full Text
- View/download PDF
40. Copd And The Risk For Myocardial Infarction By Type In People With Hiv
- Author
-
Crothers, Kristina, Nance, Robin M., Whitney, Bridget M., Harding, Barbara N., Heckbert, Susan R., Budoff, Matthew J., Mathews, William C., Bamford, Laura, Cachay, Edward R., Eron, Joseph J., Napravnik, Sonia, Moore, Richard D., Keruly, Jeanne C., Willig, Amanda, Burkholder, Greer, Feinstein, Matthew J., Saag, Michael S., Kitahata, Mari M., Crane, Heidi M., and Delaney, Joseph A.C.
- Published
- 2022
- Full Text
- View/download PDF
41. The HIV Index Is Associated With Retention in Care Among Latinx Persons Living With HIV in the CFAR Network of Integrated Clinical Systems Cohort.
- Author
-
Salazar, Jorge, Lisha, Nadra E., Neilands, Torsten B., Ludwig-Barron, Natasha, Johnson, Mallory O., Cachay, Edward R., Napravnik, Sonia, Crane, Heidi M., Moore, Richard D., Fredericksen, Robert J., Mayer, Kenneth H., Christopoulos, Katerina A., and Sauceda, John A.
- Abstract
The HIV Index is a validated self-report scale of engagement in HIV care previously correlated with future retention and virologic suppression. However, its performance in a monoethnic Latinx population has not been studied. We evaluated the HIV Index among Latinx persons living with HIV in the Centers for AIDS Research Network of Integrated Clinical Systems cohort and performed multivariable logistic regression to estimate its association with primary outcomes of suboptimal retention (not keeping 100% of HIV clinic appointments) and virologic suppression (HIV viral load <200 copies/mL). The mean Index score was 4.5 (standard deviation 0.6) in both analytic samples, indicative of feeling well-engaged. Higher Index scores were associated with lower odds of suboptimal retention (OR = 0.12, 95% CI [0.03, 0.54], p =.005), however, there was no association between Index score and virologic suppression. The HIV Index is useful for assessing engagement and retention among Latinx PLWH in routine care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Brief Report
- Author
-
Merlin, Jessica S, Long, Dustin, Becker, William C, Cachay, Edward R, Christopoulos, Katerina A, Claborn, Kasey, Crane, Heidi M, Edelman, E Jennifer, Harding, Richard, Kertesz, Stefan G, Liebschutz, Jane M, Mathews, W Christopher, Mugavero, Michael J, Napravnik, Sonia, C OʼCleirigh, Connall, Saag, Michael S, Starrels, Joanna L, and Gross, Robert
- Subjects
Pain Research ,Clinical Research ,HIV/AIDS ,Chronic Pain ,Management of diseases and conditions ,7.1 Individual care needs ,Adult ,Analgesics ,Opioid ,Female ,HIV Infections ,Humans ,Male ,Middle Aged ,Prospective Studies ,Treatment Outcome ,Viral Load ,chronic pain ,HIV ,opioids ,virologic failure ,retention in care ,Clinical Sciences ,Public Health and Health Services ,Virology - Abstract
BackgroundChronic pain occurs in up to 85% of persons living with HIV and is commonly treated with long-term opioid therapy (LTOT). We investigated the impact of chronic pain and LTOT on HIV outcomes.MethodsThis was prospective cohort study conducted between July 2015 and July 2016 in 5 HIV primary care clinics. Chronic pain was defined as ≥moderate pain for ≥3 months on the Brief Chronic Pain Questionnaire. Chronic pain and LTOT were assessed at an index visit. Suboptimal retention, defined as at least one "no-show" to primary care, and virologic failure were measured over the subsequent year. Multivariable logistic regression models were built for each outcome adjusting for site.ResultsAmong 2334 participants, 25% had chronic pain, 27% had suboptimal retention, 12% had virologic failure, and 19% were prescribed LTOT. Among individuals not on LTOT, chronic pain was associated with increased odds of suboptimal retention [adjusted odds ratio (aOR) 1.46, 95% confidence interval (CI): 1.10 to 1.93, P = 0.009] and virologic failure (aOR 1.97, 95% CI: 1.39 to 2.80, P < 0.001). Among individuals with chronic pain, there was no association between LTOT and retention, but LTOT was associated with lower rates of virologic failure (aOR 0.56, 95% CI: 0.33 to 0.96, P = 0.03).ConclusionsChronic pain in participants not on LTOT was associated with virologic failure. This reinforces the need to identify effective chronic pain treatments for persons living with HIV and investigate their impact on HIV outcomes. The apparent protective association between LTOT and virologic failure in those with pain merits further exploration.
- Published
- 2018
43. Predictors of Missed Hepatitis C Intake Appointments and Failure to Establish Hepatitis C Care Among Patients Living With HIV.
- Author
-
Cachay, Edward R, Hill, Lucas, Torriani, Francesca, Ballard, Craig, Grelotti, David, Aquino, Abigail, and Christopher Mathews, W
- Subjects
DAA ,HCV ,HIV ,drug use ,mental health disorders - Abstract
BackgroundWe estimated and characterized the proportion of patients living with HIV (PLWH) who missed hepatitis C (HCV) intake appointments and subsequently failed to establish HCV care.MethodsLogistic regression analyses were used to identify factors associated with missed HCV intake appointments and failure to establish HCV care among PLWH referred for HCV treatment between January 2014 and December 2017. In addition to demographics, variables included HIV treatment characteristics, type of insurance, liver health status, active alcohol or illicit drug use, unstable housing, and history of a mental health disorder (MHD).ResultsDuring the study period, 349 new HCV clinic appointments were scheduled for 202 unduplicated patients. Approximately half were nonwhite, and 80% had an undetectable HIV viral load. Drug use (31.7%), heavy alcohol use (32.8%), and MHD (37.8%) were prevalent. Over the 4-year period, 21.9% of PLWH referred for HCV treatment missed their HCV intake appointment. The proportion increased each year, from 17.2% in 2014 to 25.4% in 2017 (P = .021). Sixty-six of the 202 newly referred HCV patients (32.7%) missed their first HCV appointment, and 28 of these (42.4%) failed to establish HCV care. Having a history of MHD, CD4
- Published
- 2018
44. A 35-Year-Old Human Immunodeficiency Virus-Infected Male With Abdominal Pain and a Knot in His Abdomen
- Author
-
Cachay, Edward R, Berndtson, Allison E, Brouha, Sharon, and Wang, Huan-You
- Subjects
Biological Sciences ,Medical and Health Sciences ,Microbiology - Published
- 2018
45. Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment
- Author
-
Cachay, Edward R, Ballard, Craig, Colwell, Bradford, Torriani, Francesca, Hicks, Charles, and Mathews, Wm Christopher
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Hepatitis ,Chronic Liver Disease and Cirrhosis ,Digestive Diseases ,HIV/AIDS ,Hepatitis - C ,Liver Disease ,Emerging Infectious Diseases ,Infectious Diseases ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Adult ,Antiviral Agents ,Coinfection ,Drug Therapy ,Combination ,Female ,HIV Infections ,Hepacivirus ,Hepatitis C ,Chronic ,Humans ,Interferon-alpha ,Male ,Middle Aged ,Oligopeptides ,Polyethylene Glycols ,Retrospective Studies ,Ribavirin ,Surveys and Questionnaires ,Treatment Outcome ,HIV ,HCV treatment ,Symptoms ,Monitoring ,Virology ,Clinical sciences - Abstract
BackgroundClinicians are incorporating patient-reported outcomes in the management of HIV-infected persons co-infected with hepatitis C virus (HCV), but there are no validated inventories to monitor symptoms of patients during HCV therapy.DesignFive-year retrospective cohort analysis of persons living with HIV (PLWH) treated for HCV.MethodsThe HCV symptom-inventory (HCV-SI) was administered before, during, and after HCV treatment. Discriminant validity was assessed, separately, in mixed model linear regression of HCV-SI T-scores on treatment regimens (pegylated-interferon and ribavirin; pegylated-interferon, ribavirin, and telaprevir; and interferon-free antivirals); and side effect-related premature treatment discontinuation (SE-DC).ResultsFrom the 103 patients who completed the HCV-SI, 7% were female, 26% non-white, 32% cirrhotics and 91% had undetectable HIV viral loads. Most had genotype 1 (83%) and were HCV treatment-naïve (78%). We treated 19% of patients with pegylated-interferon and ribavirin, 22% with pegylated-interferon, ribavirin, and telaprevir and 59% received interferon-free antivirals. Overall, 77% achieved a sustained virologic response, and 6% discontinued HCV treatment due to side effects. In the treatment discrimination model, compared to the no treatment period, HCV-SI scores were significantly (p
- Published
- 2017
46. Increasing Primary Incidence of Hepatitis C Among HIV-Infected Men Who Have Sex with Men in San Diego; a Pooled Analysis of Two Large Clinics from 2000-2015
- Author
-
Chaillon, Antoine, Sun, Xiaoying, Cachay, Edward R, Looney, David, Wyles, David L, Garfein, Richard L, Anderson, Christy M, Martin, Thomas C, Jain, Sonia, Mehta, Sanjay R, Smith, Davey M, Little, Susan J, and Martin, Natasha K
- Subjects
Gastroenterology & Hepatology ,Medical Biochemistry and Metabolomics ,Clinical Sciences ,Immunology - Published
- 2017
47. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
- Author
-
Park, Han-Sol, primary, Yin, Anna, additional, Barranta, Caelan, additional, Lee, John S., additional, Caputo, Christopher A., additional, Sachithanandham, Jaiprasath, additional, Li, Maggie, additional, Yoon, Steve, additional, Sitaras, Ioannis, additional, Jedlicka, Anne, additional, Eby, Yolanda, additional, Ram, Malathi, additional, Fernandez, Reinaldo E., additional, Baker, Owen R., additional, Shenoy, Aarthi G., additional, Mosnaim, Giselle S., additional, Fukuta, Yuriko, additional, Patel, Bela, additional, Heath, Sonya L., additional, Levine, Adam C., additional, Meisenberg, Barry R., additional, Spivak, Emily S., additional, Anjan, Shweta, additional, Huaman, Moises A., additional, Blair, Janis E., additional, Currier, Judith S., additional, Paxton, James H., additional, Gerber, Jonathan M., additional, Petrini, Joann R., additional, Broderick, Patrick B., additional, Rausch, William, additional, Cordisco, Marie Elena, additional, Hammel, Jean, additional, Greenblatt, Benjamin, additional, Cluzet, Valerie C., additional, Cruser, Daniel, additional, Oei, Kevin, additional, Abinante, Matthew, additional, Hammitt, Laura L., additional, Sutcliffe, Catherine G., additional, Forthal, Donald N., additional, Zand, Martin S., additional, Cachay, Edward R., additional, Raval, Jay S., additional, Kassaye, Seble G., additional, Marshall, Christi E., additional, Yarava, Anusha, additional, Lane, Karen, additional, McBee, Nichol A., additional, Gawad, Amy L., additional, Karlen, Nicky, additional, Singh, Atika, additional, Ford, Daniel E., additional, Jabs, Douglas A., additional, Appel, Lawrence J., additional, Shade, David M., additional, Lau, Bryan, additional, Ehrhardt, Stephan, additional, Baksh, Sheriza N., additional, Shapiro, Janna R., additional, Ou, Jiangda, additional, Na, Yu Bin, additional, Knoll, Maria D., additional, Ornelas-Gatdula, Elysse, additional, Arroyo-Curras, Netzahualcoyotl, additional, Gniadek, Thomas J., additional, Caturegli, Patrizio, additional, Wu, Jinke, additional, Ndahiro, Nelson, additional, Betenbaugh, Michael J., additional, Ziman, Alyssa, additional, Hanley, Daniel F., additional, Casadevall, Arturo, additional, Shoham, Shmuel, additional, Bloch, Evan M., additional, Gebo, Kelly A., additional, Tobian, Aaron A.R., additional, Laeyendecker, Oliver, additional, Pekosz, Andrew, additional, Klein, Sabra L., additional, and Sullivan, David J., additional
- Published
- 2024
- Full Text
- View/download PDF
48. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras
- Author
-
Klein, Marina B, Althoff, Keri N, Jing, Yuezhou, Lau, Bryan, Kitahata, Mari, Re, Vincent Lo, Kirk, Gregory D, Hull, Mark, Kim, H Nina, Sebastiani, Giada, Moodie, Erica EM, Silverberg, Michael J, Sterling, Timothy R, Thorne, Jennifer E, Cescon, Angela, Napravnik, Sonia, Eron, Joe, Gill, M John, Justice, Amy, Peters, Marion G, Goedert, James J, Mayor, Angel, Thio, Chloe L, Cachay, Edward R, Moore, Richard, Research and Design of IeDEA, for the North American AIDS Cohort Collaboration on, Benson, Constance A, Bosch, Ronald J, Boswell, Stephen, Mayer, Kenneth H, Grasso, Chris, Hogg, Robert S, Harrigan, P Richard, Montaner, Julio SG, Samji, Hasina, Brooks, John T, Buchacz, Kate, Gebo, Kelly A, Moore, Richard D, Rodriguez, Benigno, Horberg, Michael A, Jacobsonc, Lisa P, D'Souza, Gypsyamber, Rourke, Sean B, Burchell, Ann N, Rachlis, Anita R, Hunter-Mellado, Robert F, Mayor, Angel M, Deeks, Steven G, Martin, Jeffrey N, Patel, Pragna, Saag, Michael S, Mugavero, Michael J, Willig, James, Eron, Joseph J, Kitahata, Mari M, Crane, Heidi M, Drozd, Daniel R, Haas, David, Bebawy, Sally, Turner, Megan, Justice, Amy C, Dubrow, Robert, Fiellin, David, Gange, Stephen J, Anastos, Kathryn, McKaig, Rosemary G, Freeman, Aimee M, Lent, Carol, Van Rompaey, Stephen E, Morton, Liz, McReynolds, Justin, Lober, William B, and Abraham, Alison G
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Hepatitis ,Emerging Infectious Diseases ,Chronic Liver Disease and Cirrhosis ,Hepatitis - C ,Digestive Diseases ,Liver Disease ,Hepatitis - B ,Sexually Transmitted Infections ,Infectious Diseases ,HIV/AIDS ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Adult ,Aged ,Alcohol Drinking ,Anti-HIV Agents ,Canada ,Cohort Studies ,Coinfection ,End Stage Liver Disease ,Female ,HIV Infections ,Hepatitis B ,Hepatitis C ,Humans ,Incidence ,Male ,Middle Aged ,Risk Factors ,United States ,HIV ,hepatitis C virus ,hepatitis B virus ,coinfection ,end-stage liver disease ,North American AIDS Cohort Collaboration on Research and Design of IeDEA ,North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
BackgroundHuman immunodeficiency virus (HIV)-infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses are at increased risk of end-stage liver disease (ESLD). Whether modern antiretroviral therapy has reduced ESLD risk is unknown.MethodsTwelve clinical cohorts in the United States and Canada participating in the North American AIDS Cohort Collaboration on Research and Design validated ESLD events from 1996 to 2010. ESLD incidence rates and rate ratios according to hepatitis status adjusted for age, sex, race, cohort, time-updated CD4 cell count and HIV RNA were estimated in calendar periods corresponding to major changes in antiretroviral therapy: early (1996-2000), middle (2001-2005), and modern (2006-2010) eras.ResultsAmong 34 119 HIV-infected adults followed for 129 818 person-years, 380 incident ESLD outcomes occurred. ESLD incidence (per 1000 person-years) was highest in triply infected (11.57) followed by HBV- (8.72) and HCV- (6.10) coinfected vs 1.27 in HIV-monoinfected patients. Adjusted incidence rate ratios (95% confidence intervals) comparing the modern to the early antiretroviral era were 0.95 (.61-1.47) for HCV, 0.95 (.40-2.26) for HBV, and 1.52 (.46-5.02) for triply infected patients. Use of antiretrovirals dually activity against HBV increased over time. However, in the modern era, 35% of HBV-coinfected patients were not receiving tenofovir. There was little use of HCV therapy.ConclusionsDespite increasing use of antiretrovirals, no clear reduction in ESLD risk was observed over 15 years. Treatment with direct-acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized for coinfected patients.
- Published
- 2016
49. Viral Suppression Trajectories Destabilized After Coronavirus Disease 2019 Among US People With Human Immunodeficiency Virus: An Interrupted Time Series Analysis.
- Author
-
Spinelli, Matthew A, Christopoulos, Katerina A, Moreira, Carlos V, Jain, Jennifer P, Lisha, Nadra, Glidden, David V, Burkholder, Greer A, Crane, Heidi M, Shapiro, Adrienne E, Jacobson, Jeffrey M, Cachay, Edward R, Mayer, Kenneth H, Napravnik, Sonia, Moore, Richard D, Gandhi, Monica, and Johnson, Mallory O
- Subjects
HIV prevention ,VIRAL load ,RESEARCH funding ,HIV-positive persons ,TIME series analysis ,LONGITUDINAL method ,RACE ,RESEARCH ,COVID-19 pandemic - Abstract
We examined changes in the proportion of people with human immunodeficiency virus (PWH) with virologic suppression (VS) in a multisite US cohort before and since the coronavirus disease 2019 (COVID-19) pandemic. Overall, prior gains in VS slowed during COVID-19, with disproportionate impacts on Black PWH and PWH who inject drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV
- Author
-
Kim, H. Nina, Nance, Robin M., Lo Re, Vincent, III, Silverberg, Michael J., Franco, Ricardo, Sterling, Timothy R., Cachay, Edward R., Horberg, Michael A., Althoff, Keri N., Justice, Amy C., Moore, Richard D., Klein, Marina, Crane, Heidi M., Delaney, Joseph A., and Kitahata, Mari M.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.